Previous 10 | Next 10 |
2024-04-17 07:04:07 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets GLP-1s ...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...
2024-04-15 04:31:00 ET Summary Jazz Pharmaceuticals is rated as a "Buy" due to its current financial health, multiple near-term catalysts, and projected growth for 2024 and 2025. The company's successful commercial products include Xywav, Epidiolex, and Rylaze, which have shown in...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 123.3% to $0.516 on volume of 328,807,701 shares PROSHARES TRUST (SQQQ) rose 4.7% to $10.89 on volume of 174,876,648 shares Nikola Corporation (NKLA) fell 2.3% to $0.7003 on volume of 136,204,677 share...
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting PR Newswire Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in tre...
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer PR Newswire Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanid...
Oncology is a tricky sector in which to innovate, but we can start by optimizing existing combination approaches NORTHAMPTON, MA / ACCESSWIRE / March 28, 2024 / Jazz Pharmaceuticals By Liz Henderson Liz Henderson, Sr. Vice President Technical Operations at Jazz Pharmaceuticals discusses...
2024-03-23 17:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-20 13:30:07 ET UBS analyst issues BUY recommendation for JAZZ on March 20, 2024 10:00AM ET. The previous analyst recommendation was Buy. JAZZ was trading at $124.43 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst r...
2024-03-20 11:30:01 ET RBC Capital analyst issues UNDERPERFORM recommendation for JAZZ on March 20, 2024 10:00AM ET. The previous analyst recommendation was Underperform. JAZZ was trading at $124.43 at issue of the analyst recommendation. The overall analyst consensus : ...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...